title: Practical considerations of recombinant human erythropoietin therapy.
abstract: The effect of long-term hemodialysis in 58 nonanemic end-stage renal disease patients treated with recombinant human erythropoietin (r-HuEPO; EPOGEN [epoetin alfa], AMGEN Inc, Thousand Oaks, CA) has been examined in detail. Increased dialyzer prescription (Kt/V) was correlated with the need for a lower maintenance dose of r-HuEPO. After 1 year of therapy, stable increases in hemoglobin, hematocrit, and reticulocyte levels were obtained without other clinically significant hematologic changes. In a randomly selected subgroup of 14 patients, 5 developed predialysis increased diastolic pressures. In this group, an early increase in cardiac output and ejection fraction was accompanied by a decrease in total peripheral resistance index (TPRI). Later changes showed a steady increase in TPRI with an associated mild increase in mean arterial pressure. A slight increase in cardiac responsiveness to fistula occlusive maneuvers was also found. Hospital admissions and mortality rates were not significantly different from those of a cohort control population. At a fixed Kt/V there were slight decreases in solute clearances with correction of anemia, with phosphate, urate, and creatinine changing significantly. Corrective measures required simple compensatory adjustments in dialysis blood-flow rates. Intradialytic complications were noticeably improved. Patients receiving long-term r-HuEPO replacement therapy do remarkably well without major complications.
authors.affiliation: Section of Dialysis and Extracorporeal Therapy, Cleveland Clinic Foundation, OH 44106.
authors.forename: E P
authors.initials: EP
authors.lastname: Paganini
authors.forename: D
authors.initials: D
authors.lastname: Latham
authors.forename: M
authors.initials: M
authors.lastname: Abdulhadi
mesh_terms: D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004921:Erythropoietin / Q000627:therapeutic use*; D006400:Hematocrit; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D011994:Recombinant Proteins / Q000627:therapeutic use*; D006435:Renal Dialysis
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin